Efficacy Observation of Montelukast Sodium Combined with Fluticasone Propionate Inhalation in the Treatment of Cough-Variant Asthma in Children

LI Juan; QIU Wenli

doi:10.13919/j.issn.2095-6274.ZHJY202412017

Abstract：Objective This study aims to investigate the clinical efficacy of nebulized montelukast sodium tablets combined with fluticasone propionate in the treatment of cough variant asthma.Methods A retrospective analysis was conducted on the clinical data of 80 children diagnosed with cough variant asthma at Putian Overseas Chinese Hospital from January 2021 to January 2024.Based on the treatment regimen,the children were divided into an observation group(montelukast sodium+nebulized fluticasone propionate,40 cases)and a control group(nebulized fluticasone propionate,40 cases).Clinical efficacy,pulmonary function parameters,airway remodeling indicators,in-flammatory markers,and adverse event occurrences were compared between the two groups.Results The overall clinical efficacy rate in the observation group was significantly higher than that in the control group(P<0.05).Prior to treatment,there were no significant differences in pulmonary function parameters[forced vital capacity(FVC),peak expiratory flow(PEF),forced expiratory volume in one second(FEV1)],airway remodeling indicators[lumen area(LA),wall area(WA),total airway area(TA)],or inflammatory markers[interleukin-4(IL-4),interleukin-10(IL-10),eosinophils(EOS)]between the two groups(P<0.05).Post-treatment,both groups exhibited significant im-provements in FVC,PEF,FEV1,LA,and IL-10 levels(P<0.001),while WA,TA,IL-4,and EOS levels signifi-cantly decreased(P<0.05).Furthermore,the observation group showed notably higher levels of FVC,PEF,FEV1,LA,TA,and IL-10(P<0.05)and significantly lower levels of WA,IL-4,and EOS compared to the control group(P<0.001).The incidence of adverse reactions during treatment did not differ significantly between the observation and control groups(P>0.05).Conclusion The treatment regimen of nebulized montelukast sodium combined with fluticasone propionate demonstrates significant clinical efficacy in children with cough variant asthma.This combination effec-tively improves pulmonary function,alleviates airway inflammation,inhibits airway remodeling,and presents a low risk of adverse reactions,warranting its promotion in clinical practice.